Amanat Acquisition Corp. (AMAN) · Oct 26, 2026 · Material agreement
Sole-holder support — 100% of Corxel shares committed to approve the merger
Amanat’s acquisition of Corxel gains binding support from its sole stockholder, clearing a key approval step but adding little beyond deal mechanics.
Corxel is moving an oral obesity drug toward larger global trials. The clinical-stage biotech is building a cardiometabolic pipeline led by CX11, an oral small-molecule GLP-1 drug, after positive Phase 2 data and with plans to advance toward pivotal Phase 3 development. This filing does not change that operating story; it formalizes the transaction mechanics needed to put the company under Amanat’s public-company structure.
The merger now has locked-in support from Corxel’s controlling holder. Corxel Pharmaceuticals Limited owns all 100 issued and outstanding shares of Corxel Pharmaceuticals, Inc. The holder agreed to approve the business combination and merger, oppose competing proposals, and provide written consent after the registration statement/proxy becomes effective.
The agreement also gives Amanat an enforceable backstop if the holder does not act. The proxy is irrevocable, covers any additional shares acquired by the holder, and lets Amanat vote those shares on the merger-related matters if the holder fails to comply. That reduces execution risk, but because this holder controls 100% of Corxel’s shares, the approval was effectively embedded in the deal from the outset.
This is confirmation, not a new financing or clinical milestone. The filing does not disclose transaction value, funding commitments, dilution, clinical updates, or a closing date. Relative to the standing assumption that a definitive merger agreement would include support from Corxel’s sole owner, the information is largely procedural.
Bottom line: The agreement removes Corxel stockholder-approval uncertainty and keeps the merger process on track, but it does not materially change the biotech’s underlying development story or economics yet.
Registration statement effectiveness and stockholder written consent
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!